Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -448.29 Million CNY | 55.4% |
| 2022 | -1 Billion CNY | -88.46% |
| 2021 | -533.32 Million CNY | -318.58% |
| 2020 | -127.41 Million CNY | -119.36% |
| 2019 | 658 Million CNY | 1575.15% |
| 2018 | 39.28 Million CNY | 225.58% |
| 2017 | 12.06 Million CNY | 121.46% |
| 2016 | -56.21 Million CNY | 44.08% |
| 2015 | -100.52 Million CNY | -25.42% |
| 2014 | -80.14 Million CNY | -57.89% |
| 2013 | -50.76 Million CNY | -11.81% |
| 2012 | -45.4 Million CNY | -168.84% |
| 2011 | -16.88 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 583.86 Million CNY | 1132.58% |
| 2024 Q1 | -56.54 Million CNY | 87.39% |
| 2024 Q3 | -67.16 Million CNY | -111.5% |
| 2023 Q3 | 244.84 Million CNY | 132.82% |
| 2023 Q4 | -448.29 Million CNY | -283.09% |
| 2023 FY | -448.29 Million CNY | 55.4% |
| 2023 Q1 | -346.47 Million CNY | 65.53% |
| 2023 Q2 | 105.16 Million CNY | 130.35% |
| 2022 Q4 | -1 Billion CNY | -63.31% |
| 2022 Q3 | -615.43 Million CNY | -102.12% |
| 2022 Q2 | -304.49 Million CNY | 55.0% |
| 2022 FY | -1 Billion CNY | -88.46% |
| 2022 Q1 | -676.59 Million CNY | -26.87% |
| 2021 Q1 | -153.97 Million CNY | -20.85% |
| 2021 Q3 | -398 Million CNY | -5.65% |
| 2021 Q4 | -533.32 Million CNY | -34.0% |
| 2021 FY | -533.32 Million CNY | -318.58% |
| 2021 Q2 | -376.71 Million CNY | -144.66% |
| 2020 Q2 | -14.98 Million CNY | 86.18% |
| 2020 Q3 | 119.63 Million CNY | 898.58% |
| 2020 FY | -127.41 Million CNY | -119.36% |
| 2020 Q4 | -127.41 Million CNY | -206.5% |
| 2020 Q1 | -108.39 Million CNY | -116.47% |
| 2019 Q4 | 658 Million CNY | -10.76% |
| 2019 FY | 658 Million CNY | 1575.15% |
| 2019 Q3 | 737.33 Million CNY | 190.89% |
| 2019 Q2 | 253.47 Million CNY | 221.36% |
| 2019 Q1 | 78.87 Million CNY | 100.8% |
| 2018 Q2 | -5.29 Million CNY | -134.84% |
| 2018 Q4 | 39.28 Million CNY | -35.22% |
| 2018 FY | 39.28 Million CNY | 225.58% |
| 2018 Q3 | 60.63 Million CNY | 1244.36% |
| 2018 Q1 | 15.2 Million CNY | 26.04% |
| 2017 Q2 | -63.19 Million CNY | 50.23% |
| 2017 Q1 | -126.96 Million CNY | -125.87% |
| 2017 Q3 | 18.3 Million CNY | 128.97% |
| 2017 Q4 | 12.06 Million CNY | -34.1% |
| 2017 FY | 12.06 Million CNY | 121.46% |
| 2016 Q1 | 196.23 Million CNY | 295.2% |
| 2016 Q3 | -817.88 Million CNY | -349.12% |
| 2016 Q4 | -56.21 Million CNY | 93.13% |
| 2016 FY | -56.21 Million CNY | 44.08% |
| 2016 Q2 | -182.1 Million CNY | -192.8% |
| 2015 Q1 | 5.37 Million CNY | 0.0% |
| 2015 FY | -100.52 Million CNY | -25.42% |
| 2015 Q4 | -100.52 Million CNY | -236.52% |
| 2015 Q2 | 5.37 Million CNY | 0.0% |
| 2015 Q3 | 73.63 Million CNY | 1270.32% |
| 2014 FY | -80.14 Million CNY | -57.89% |
| 2013 FY | -50.76 Million CNY | -11.81% |
| 2012 FY | -45.4 Million CNY | -168.84% |
| 2011 FY | -16.88 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 5.96 Billion CNY | 107.514% |
| Joinn Laboratories(China)Co.,Ltd. | -2.77 Billion CNY | 83.858% |
| WuXi AppTec Co., Ltd. | -4.24 Billion CNY | 89.444% |
| Thalys Medical Technology Group Inc. | 772.55 Million CNY | 158.027% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | -1.87 Billion CNY | 76.138% |
| Chemclin Diagnostics Co., Ltd. | -214.05 Million CNY | -109.429% |